The duration of use of Lorviqua mainly depends on disease progression and patient tolerance, and is usually continued until disease progression or intolerable toxicity occurs. As an ALK/ROS1 inhibitor, its long-term use requires regular evaluation of efficacy and safety.

1. Basic medication cycle

(1) Standard protocol: Daily continuous medication without fixed course restrictions, tumor response needs to be evaluated every 2-3 months.

(2) Clinical research data: The median duration of treatment in phase III trials is 18.3 months, with some patients able to exceed 3 years.

2 factors affecting the service life

(1) Disease progression: About 60% of patients terminate treatment due to drug resistance, with a median progression free survival of approximately 12-36 months.

(2) Toxic reactions: About 15% of patients discontinue medication due to adverse reactions, commonly hyperlipidemia/central nervous system side effects.

Long term medication management

(1) Therapeutic efficacy monitoring: Imaging evaluation should be conducted every 6-8 weeks, and replacement plans should be considered if new lesions appear.

(2) Safety management: Regular testing of liver function/blood lipids, medication should be suspended until recovery is achieved for grade 3-4 toxicity.

4 Special precautions

(1) Drug storage: Unopened drugs have a shelf life of 24 months and must be stored according to the instructions after opening.

(2) Combination therapy: Combination therapy with potent CYP3A inhibitors may shorten the effective treatment time and require dosage adjustment.